Day One
Wednesday 17th April 2024
8:00 am Registration & Morning Coffee
8:55 am Chair’s Opening Remarks
8:56 am
Uncovering New Targetable Pathways in Inflammatory-Mediated Disease: Forming the Basis for Developing Safe & Effective Therapies
9:00 am Itch, a Strategic Target for Treatment of Type 2 Skin Diseases
Synopsis
• Understanding shared and unique characteristics of AD, PN and CSU
• Describe the contribution of type 2 inflammation to neuroimmune dysregulation and itch in AD, PN, and CSU
• Improvement of itch and disease control with IL-4R across type 2 inflammatory skin disease
9:30 am Topical Biologics for the Treatment of Inflammatory Disorders Including Pruritus, AD, & Acne
Synopsis
• Discussion of the drug development evolution of a first-in-class therapy
• Results from previous Phase 2 studies
• Roadmapping what is next to bring these novel therapeutics to market
10:00 am Morning Break & Speed Networking
Synopsis
Meet and connect with your peers in this dedicated networking session
10:30 am Elevating Dermatological Drug Development Through Advanced Inflammatory Marker Targeting Methodology
Synopsis
• Speaking to preclinical study design to evaluate anti-interleukin 17 NanoAbs as a treatment for plaque psoriasis, which showed the downregulation of psoriasis molecular markers
• Leveraging 3D biologic skin models to mimic the structure of human skin to suggest NanoAbs’ therapeutic potential
• Demonstrating the potential for a systemic novel approach with higher affinity for IL-17F isoform to improve treatment efficacy for patients with psoriasis
10:32 am
Biomarkers in Dermatology: Building Better Patient Population Insights Into Drug Development Strategy Planning
11:30 am Biomarker-Driven Drug Development in Dermatology
Synopsis
• How leveraging and integrating methodologies, including RNA sequencing and multiomics approaches can verify drug pharmacodynamics, demonstrating efficacy and safety through biomarkers
• Investigator-initiated studies with approved drugs to validate novel endpoints
• Deep-phenotyping of patients with inflammatory skin diseases for stratification and improved disease understanding
• Case study with anti-IL-23 therapy for psoriasis, presenting recent outcomes using a technology driven approach
12:00 pm Lunch Break
Synopsis
Take this chance to meet the expert speakers, connect with your peers and explore our exhibition hall to meet fresh and familiar faces or even your next partner!
1:00 pm AI Assisted Objective Skin Imaging & Analysis of Skin Diseases & Drug Effects in Clinical Trials
Synopsis
• Standardised high quality mobile skin imaging
• Smart skin imaging data and objective image analysis
• Machine learning and AI powered decision support in trials and new digital skin biomarker and endpoints in HS and beyond
1:28 pm
Optimising Drug Delivery to Target Sites with Improved Stability & Bioavailability
1:30 pm Detailing Hedgehog-Signalling Inhibition as a Promising Target for Unmet Needs in the Dermatology Universe
Synopsis
• Exploring the mechanism of Patidegib a hedgehog inhibitor (HHI) blocker, preventing new basal cell carcinomas in Gorlin Syndrome
• Current data showcasing the potential of this mechanism and highlighting the benefits of topical HHIs over oral HHIs
2:00 pm Panel Session : Route of Administration & Formulations: How Can We Improve?
Synopsis
Delving into the complexities of selecting appropriate routes of administration and formulation strategies, learn expert takes on:
• How can biopharma better formulate drugs effectively bypass of overcome the skin’s barrier function?
• What’s needed, from a drug delivery system perspective, to ensure optimal therapeutic outcomes and reduce potential side efects?
• What do biopharma developing therapeutics for immune-mediated dermatological conditions in dermatology need to consider in relation to drug route of administration across small molecule, biologic and mAb therapies?
• How can industry improve to accelerate the development of orally administered drugs?
3:00 pm Scientific Poster Session
Synopsis
The learning & networking continues! Join us for our new scienifitc poster session, providing an opportunity to connect with peers, fostering new relationships, and a platform for showcasing your work, while also allowing you to explore cutting-edge contributions across drugd iscovery to clinical trial updates.
3:45 pm Using Nanotechnology to Help Enhance Topical Drug Delivery: Scientific Successes & Regulatory Challenges
Synopsis
• Putting patients at the heart of dermatology drug development: Optimising formulations to improve efficacy (drug delivery to target sites) / compliancy and improve patient quality of life
• Novel nanotechnology approach: Optimising formulations to improve drug targeting and delivery
• How regulatory environments impact formulation/excipient’s route to approval
Beyond Dermatology: Realising Opportunities for Disease with Inflammatory Components
4:15 pm Panel Session : Unlocking Synergies: Extending Dermatological Drug Development Insights to Address Broader Inflammatory Diseases
Synopsis
Gain insights into the extension of knowledge from immuno-dermatological drug development to encompass a broader range of inflammatory diseases, including Rheumatoid Arthritis, Systemic Lupus Erythematosus, Inflammatory Bowel Disease and more:
• How can advancements in our mechanistic understanding of dermatological drug development interactions targeting inflammatory pathways be leveraged to benefit patients with other inflammatory diseases?
• What are the key challenges in translating dermatological drug discoveries into therapies for broader inflammatory conditions, such as rheumatoid arthritis or inflammatory bowel disease?
• How can we ensure that cross-pollination efforts align with the diverse needs and experiences of patients with various inflammatory conditions?
• What strategies and initiatives can facilitate greater collaboration and knowledge sharing in the field of dermatology and broader inflammatory diseases?
• How can these advancements in precision medicine and biomarker development in dermatology be extended to identify patient populations in other inflammatory diseases who are most likely to benefit from cross-pollinated therapies, ensuring more targeted treatment approaches?
5:00 pm Chair’s Closing Remarks & End of Day One
